Category: BIOTECHNOLOGY

On Thursday, Shares of Great Basin Scientific, Inc. (NASDAQ:GBSN), surged 8.67% to $0.0940. Great Basin Scientific, declared it added 28 new customers in the third quarter of 2015. As of September 30th, the company had secured 143 U.S. customers and...

On Thursday, Shares of RXi Pharmaceuticals Corporation (NASDAQ:RXII), declined -0.74% to $0.5360. RXi Pharmaceuticals Corporation, declared that results from a blinded panel and an Investigator review show that incision sites treated with RXI-109 after scar re...

On Thursday, Shares of Aeterna Zentaris Inc. (NASDAQ:AEZS), declined -2.44% to $0.0680. Aeterna Zentaris, traded on a volume of 18,515,567, lower than its standard daily volume. The stock, as of recent close, has shown weekly downbeat performance of -24.86% wh...

On Thursday, Shares of Opko Health, Inc. (NYSE:OPK), surged 2.54% to $9.28. Cocrystal is a pharmaceutical company seeking to discover novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. Cocrystal has formerly received planned ...

On Thursday, Shares of Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), surged 6.42% to $3.98. Keryx Biopharmaceuticals, declared that it has reached a contract to raise $125 million through the private placement of Convertible Senior Notes, due 2020, with funds m...

On Thursday, Shares of Gilead Sciences Inc. (NASDAQ:GILD), surged 3.30% to $101.64. Gilead Sciences Inc. (NASDAQ:GILD) is predictable to report its quarterly earnings by the end of this month. According to Brian Abrahams, analyst at Jefferies, the biotech gian...

On Thursday, Shares of Baxalta Incorporated (NYSE:BXLT), surged 7.54% to $33.37. Baxalta Incorporated, declared that Health Canada has approved OBIZUR [Antihemophilic Factor (Recombinant), Porcine Sequence] for the treatment of bleeding episodes in patients wi...

On Wednesday, Shares of Zafgen, Inc. (NASDAQ:ZFGN), skyrocketed 23.81% to $19.50. Zafgen, issued the following statement: “Zafgen recently learned of a patient death which occurred in the Company’s ongoing double-blind, randomized, placebo-controlled P...

On Wednesday, Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT), lost -11.78% to $29.06. An FDA advisory board won’t meet to review the potential drug to treat Duchenne muscular dystrophy developed at Sarepta Therapeutics until nearly two months later than ...